Key Insights

Highlights

Treatment Research

3 treatments under study, led by Alemtuzumab

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00579137Phase 1/2Terminated

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

Showing all 1 trials

Research Network

Common Treatments

  • Alemtuzumab1
  • Stem Cell Infusion1
  • Anticd451

Active Sponsors

  • Baylor College of Medicine1
  • Center for Cell and Gene Therapy, Baylor College of Medicine1

Top Investigators

Related Conditions

  • Severe Primary Immunodeficiency Disorder1
  • Severe Combined Immunodeficiency Disease1
  • Undefined T Cell Deficiency Disorder1

Activity Timeline